Clinical course of Covid-19 in a cohort of patients with Behçet disease
Sign Up to like & getrecommendations! Published in 2021 at "Medicina Clinica"
DOI: 10.1016/j.medcli.2021.11.009
Abstract: Objective: The implications of Covid-19 in patients with Behçet´s disease (BD) are unknown. Patients with BD usually take long-term therapy with therapeutic agents that have been tested in Covid-19 patients. We aimed to assess the… read more here.
Keywords: los; pacientes con; covid; tnfi ... See more keywords
Drug-Survival Profiling of Second-Line Biologic Therapy in Rheumatoid Arthritis: Choice of Another TNFi or a Biologic of Different Mode of Action?
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac086
Abstract: OBJECTIVES Aiming to assess the best choice of second-line therapy between second-line TNF-inhibitor (TNFi) and biologics of different mode of action (BDMA-rituximab/tocilizumab/abatacept) in rheumatoid arthritis (RA) by assessing their drug-survival spanning more that 10years, after… read more here.
Keywords: survival; drug survival; tnfi; line ... See more keywords
Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab245
Abstract: OBJECTIVES The choice of second-line biologics for ankylosing spondylitis (AS) patients previously treated with a tumour necrosis factor inhibitor (TNFi) remains unclear. Here, we compared drug retention and clinical efficacy between AS patients who switched… read more here.
Keywords: tnfi; inhibitor; clinical efficacy; tnf inhibitor ... See more keywords
P136 T-cell-Specific Biomarkers of Early Treatment Response in Patients with Rheumatoid Arthritis Treated with a Tumour Necrosis Factor Inhibitor
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.177
Abstract: The use of tumour necrosis factor inhibitors (TNFi) has advanced the clinical management of rheumatoid arthritis (RA). However, only 30-40% of patients who receive initial treatment with a TNFi experience a beneficial response. The discovery… read more here.
Keywords: cell; treatment response; tnfi; treatment ... See more keywords
Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000021827
Abstract: Abstract To retrospectively evaluate initial tumor necrosis factor inhibitor (TNFi) failure patients for clinical predictors of response to a 2nd TNFi in our 4282 rheumatoid arthritis (RA) patient database. A cross-sectional retrospective manual chart review… read more here.
Keywords: necrosis factor; response; tnfi; tumor necrosis ... See more keywords
Tumor necrosis factor inhibitors are associated with a decreased risk of COVID‐19‐associated hospitalization in patients with psoriasis—A population‐based cohort study
Sign Up to like & getrecommendations! Published in 2021 at "Dermatologic Therapy"
DOI: 10.1111/dth.15003
Abstract: The risk of coronavirus disease 2019 (COVID‐19) and its complications among patients with psoriasis treated by tumor necrosis factor inhibitors (TNFis) remains to be decisively delineated. We aimed to assess the risk of COVID‐19 infection,… read more here.
Keywords: tnfi; risk; risk covid; covid ... See more keywords
FRI0213 Comparative effectiveness of abatacept, rituximab, tocilizumab and anti-tnf biological dmards in ra: results from the nationwide swedish register
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1307
Abstract: Background Many current guidelines rank abatacept (ABA), rituximab (RTX), tocilizumab (TOC), and the TNFi bDMARDs as equal in effectiveness for the treatment of RA, at least as second line therapies. This is mainly based on… read more here.
Keywords: drug; tnfi; pfizer roche; effectiveness ... See more keywords
SAT0449 Sex, metabolic co-morbidities and line of therapy predict tnf-inhibitor therapy persistence in psoriatic arthritis: a retrospective cohort study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.5178
Abstract: Background Although tumour necrosis factor-alpha inhibitor (TNFi) therapy has proven efficacy in the management of psoriatic arthritis (PsA), relatively little is known about predictors of TNFi persistence. Such knowledge would assist the application of stratified… read more here.
Keywords: tnfi; tnfi persistence; line; persistence ... See more keywords
SAT0208 Cycling versus swapping in patients with rheumatoid arthritis with an inadequate response to at least one tumor necrosis factor alpha inhibitor: a systematic review and meta-analysis of observational studies
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.6490
Abstract: Background In patients with rheumatoid arthritis (RA) who do not respond or lose response, opinions are divided on whether it is better to try an alternative TNFi (cycling) or switch to a therapy with a… read more here.
Keywords: tnfi; response; cycling versus; rheumatology ... See more keywords
Methotrexate and BAFF interaction prevents immunization against TNF inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-213403
Abstract: Objectives TNF inhibitors (TNFi) can induce anti-drug antibodies (ADA) in patients with autoimmune diseases (AID) leading to clinical resistance. We explored a new way of using methotrexate (MTX) to decrease this risk of immunisation. Methods… read more here.
Keywords: tnfi; baff; bafftg mice; mtx ... See more keywords
OP0116 Impact of tnf inhibitors on need for joint replacement in patients with rheumatoid arthritis: a matched cohort analysis of uk biologics registry data
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1385
Abstract: Background Previous ecological data from the UK and Denmark suggest a decline in the incidence of joint replacements for RA patients following the introduction of tumour necrosis factor inhibitors (TNFi). However, patient-level data on the… read more here.
Keywords: tnfi; none declared; thr tkr; use ... See more keywords